| 10 -0.17 (-1.67%) | 03-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.59  |
1-year : | 13.17 |
| Resists | First : | 10.78 |
Second : | 11.27 |
| Pivot price | 10.65 |
|||
| Supports | First : | 9.97 |
Second : | 8.29 |
| MAs | MA(5) : | 10.2 |
MA(20) : | 10.78 |
| MA(100) : | 10.03  |
MA(250) : | 9.98 |
|
| MACD | MACD : | -0.2 |
Signal : | 0 |
| %K %D | K(14,3) : | 7.8 |
D(3) : | 11.7 |
| RSI | RSI(14): 34.7 |
|||
| 52-week | High : | 11.35 | Low : | 8.71 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ HLN ] has closed above bottom band by 8.5%. Bollinger Bands are 93.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.19 - 10.28 | 10.28 - 10.34 |
| Low: | 9.76 - 9.89 | 9.89 - 9.97 |
| Close: | 9.85 - 10.06 | 10.06 - 10.19 |
Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom.
Thu, 12 Mar 2026
Haleon PLC Sponsored ADR (NYSE:HLN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Wed, 11 Mar 2026
Haleon Strengthens Commitment to China as Consumers Focus on Better Everyday Health - ChartMill
Sun, 08 Mar 2026
Haleon (HLN) Reports 3% Organic Growth in 2025 Driven by ‘Win as One’ Strategy - Insider Monkey
Sat, 07 Mar 2026
Pitcairn Co. Cuts Stake in Haleon PLC Sponsored ADR $HLN - MarketBeat
Fri, 27 Feb 2026
Haleon PLC stock ticks up after earnings whiplash; here’s what matters for HLN shares - TechStock²
Fri, 27 Feb 2026
Haleon: Decent Earnings Growth Is Already Reflected In Valuation (NYSE:HLN) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 4,450 (M) |
| Shares Float | 8,840 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 12.7 (%) |
| Shares Short | 18,580 (K) |
| Shares Short P.Month | 19,930 (K) |
| EPS | 0.49 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.47 |
| Profit Margin | 15.1 % |
| Operating Margin | 22.9 % |
| Return on Assets (ttm) | 4.6 % |
| Return on Equity (ttm) | 10.2 % |
| Qtrly Rev. Growth | 0.6 % |
| Gross Profit (p.s.) | 1.6 |
| Sales Per Share | 2.47 |
| EBITDA (p.s.) | 0.61 |
| Qtrly Earnings Growth | 92 % |
| Operating Cash Flow | 2,630 (M) |
| Levered Free Cash Flow | 1,370 (M) |
| PE Ratio | 20.4 |
| PEG Ratio | 0 |
| Price to Book value | 4.04 |
| Price to Sales | 4.03 |
| Price to Cash Flow | 16.92 |
| Dividend | 0.05 |
| Forward Dividend | 0 |
| Dividend Yield | 0.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|